ReviewFrontiers in pharmacology2026
MircoRNAs as regulators of regulated cell death in cancer progression: a focus on ferroptosis, anoikis and pyroptosis.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer progression is shaped not only by genetic alterations but also by dynamic remodeling of regulated cell death. MicroRNAs (miRNAs) have emerged as central regulators of these processes by coordinating gene expression, metabolic balance, and stress responses. This review summarizes current understanding of how miRNAs modulate ferroptosis, anoikis, and pyroptosis across liver, lung, gastric, breast, and other cancers. They influence ferroptosis through lipid peroxidation and antioxidant systems, regulate anoikis via integrin signaling and cytoskeletal remodeling, and tune pyroptosis through inflammasome activation and gasdermin-mediated pore formation. Emerging evidence suggests that miRNAs function as integrative nodes linking metabolic reprogramming, immune-inflammatory signaling, and adaptive survival pathways. Their stability, druggability, and cross-pathway influence highlight their promise as biomarkers and therapeutic targets, and advancing RNA-based technologies may enable more precise manipulation of cell-death programs to overcome resistance and refine cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.